$-0.72
(Market cap
$1,728 Mln
Recently Viewed
Clear AllMarket cap
$1,728 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
163.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.5
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
60,240,072
CFO
$-203.37 Mln
EBITDA
$-229.89 Mln
Net Profit
$-241.99 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Galecto Inc (GLTO)
| 7.3 | 7.0 | -4.2 | 797.8 | -21.7 | -30.3 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Galecto Inc (GLTO)
| 394.8 | -73.9 | -37.4 | -62.0 | -75.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Galecto Inc (GLTO)
|
24.7 | 1,728.3 | 0.0 | -209.8 | -- | -163.8 | -- | 163.8 |
| 74.8 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 64.2 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.1 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 90.3 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.8 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 517.0 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 414.9 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 106.2 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 337.1 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of... ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark. Read more
Co-Founder, President, CEO & Director
Dr. Hans T. Schambye M.D., Ph.D.
Co-Founder, President, CEO & Director
Dr. Hans T. Schambye M.D., Ph.D.
Headquarters
Copenhagen
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Galecto Inc (GLTO) is $24.69 (NASDAQ) as of 24-Apr-2026 09:30 EDT. Galecto Inc (GLTO) has given a return of -21.73% in the last 3 years.
Since, TTM earnings of Galecto Inc (GLTO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-0.22
|
0.29
|
|
2023
|
-0.02
|
0.02
|
|
2022
|
-0.02
|
0.02
|
|
2021
|
-0.06
|
0.03
|
The 52-week high and low of Galecto Inc (GLTO) are Rs 38.33 and Rs 2.45 as of 27-Apr-2026.
Galecto Inc (GLTO) has a market capitalisation of $ 1,728 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Galecto Inc (GLTO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.